BRCA1 siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemBRCA1 siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-29219
Quantity10 µM
Gene Namebreast cancer 1, early onset
Specieshuman
TypesiRNA/dsRNA
NCBI Full Gene NameBRCA1 DNA repair associated
NCBI Gene AliasesBRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4, PPP1R53, PSCP, RNF53

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancersCommun BiolOctober 1, 2025Kai Doberstein, Johannes Panther, Eric Hahnen, Lisa Richters, Philip C. Schouten, Philipp Harter, Florian Heitz, Stefan Kommoss, Sebastian Berlit, Benjamin Tuschy, et al.transcripts of ENSG00000272172.1. For the knock down of BRCA1, we used the commercially validated siRNA sc-29219 from Santa Cruz Biotechnology (Dallas, USA). As a negative control the SR30004, Trilencer-27 Universal

(2) FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-αCell Mol Biol LettJuly 6, 2025Jun Xu, Xiaoyu Yang, Peng Shu, Wei Wang, Haibo Wu, Zhe Wang21334).(3)BRCA1 knockdown gene construction: The BRCA1 siRNA vector was purchased from Santa Cruz Biotechnology (sc-29219), with a non-targeting shRNA as the control vector. BT-549 cell lines were divided into CON and BRCA1

(3) Profilin-1 regulates DNA replication forks in a context-dependent fashion by interacting with SNF2H and BOD1LNature communicationsNovember 1, 2022Zhu C, Iwase M, Li Z, Wang F, Quinet A, Vindigni A, Shao J.RC203775). Small interfering RNAs targeting human BOD1L/FAM44A (#sc-88933), SMARCAL1 (#sc-63042), BRCA1 (#sc-29219), BRCA2 (#sc-29825), and FBH1/FBXO18 (#sc-90469) were purchased from Santa Cruz Biotechnology, Inc. Transfections

(4) Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathwayExperimental cell researchNovember 1, 2022Sinha S, Chatterjee S, Paul S, Das B, Dash SR, Das C, Kundu CN.

(5) BRCA1-BARD1 regulates transcription through modulating topoisomerase IIβOpen biologyOctober 1, 2021Bunch H, Jeong J, Kang K, Jo DS, Cong ATQ, Kim D, Kim D, Cho DH, Lee YM, Chen BPC, et al.6568, Cell Signaling) or BARD1 siRNA duplexes (SR300400, Origene) and BRCA1-targeting siRNA species (sc-29219, Santa Cruz Biotechnology) dissolved in serum-free DMEM using Lipofectamine 2000 (Invitrogen) according

(6) Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse modelInternational journal of biological sciencesJanuary 1, 2021Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, et al.

(7) Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer modelsJournal of cellular and molecular medicineSeptember 1, 2020Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.and transfection For the siRNA transfection experiments, we use siRNA for stable knockdown of c‐MET (sc‐35924), BRCA1 (sc‐29219) and BRCA2 (sc‐29825) and control (sc‐37007) from Santa Cruz Biotechnology and Lipofectamine 3000 (#L3000‐15

(8) Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trialsJournal of cancer research and clinical oncologyMarch 1, 2020Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, et al.

(9) β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissueCarcinogenesisNovember 25, 2019Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.

(10) Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradationCell death and differentiationMay 1, 2019Kim S, Jin H, Seo HR, Lee HJ, Lee YS.

(11) Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumorsExperimental & molecular medicineOctober 16, 2018Choi EK, Lim JA, Kim JK, Jang MS, Kim SE, Baek HJ, Park EJ, Kim TH, Deng CX, Wang RH, et al.

(12) Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumorsInternational journal of biological sciencesJanuary 1, 2018Baek HJ, Kim SE, Kim JK, Shin DH, Kim TH, Kim KG, Deng CX, Kim SS.

(13) BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitorsTumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineOctober 1, 2017Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.small interfering RNAs (siRNAs; Santa Cruz Biotechnology, Dallas, TX, USA): CTRL A (sc-37007), BRCA1 (sc-29219), CDK12 (sc-44531), CDK13 (sc-72836), and CDK12_2 (Sigma-Aldrich, SIHK0490) using Lipofectamine RNAi MAX

(14) BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancerOncogenesisSeptember 4, 2017Sengodan SK, Nadhan R, Nair RS, Hemalatha SK, Somasundaram V, Sushama RR, Rajan A, Latha NR, Varghese GR, Thankappan RK, et al.(sc-39540, Santa Cruz Biotechnology) and 4 nmoles of BRCA1 siRNA (4507241, Eurogentec), BRCA1 siRNA (sc-29219, Santa Cruz Biotechnology) and the transfection reagent, IcaFectin 442 (Eurogentec, 442-500) were used

(15) Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signalingBiochemical and biophysical research communicationsOctober 28, 2016Xu X, Lv YG, Yan CY, Yi J, Ling R.

(16) BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cellsOncotargetOctober 20, 2015Ambrosini G, Sawle AD, Musi E, Schwartz GK.and plasmid transfections Small interfering RNA against c-Myc (sc-29226), Rad51 (sc-36361), Brca1 (sc-29219), Wee1 (sc-36835) and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. Bcl-xL

(17) MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1Tumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineMarch 1, 2015He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X.

(18) Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancyHuman mutationMay 1, 2014Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, Li H, Hu S, Weng Y, Yen Y.

(19) Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARPMolecular medicine (Cambridge, Mass.)September 1, 2011Kim H, Naura AS, Errami Y, Ju J, Boulares AH.

(20) Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approachNutrition and cancerJanuary 1, 2010Satih S, Chalabi N, Rabiau N, Bignon YJ, Bernard-Gallon DJ.